Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do an ELI LILLY stock analysis and discuss the risks and upside potential of LILLY stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
08 Aug 2025, 22:40 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do an ELI LILLY stock analysis and discuss the risks and upside potential of LILLY stock
Source overview

AI-generated source summary

The analysis discusses Eli Lilly's (LLY) recent performance and future prospects. LLY is currently trading at $640, down 14% after reporting earnings. The earnings report was strong, with EPS at $6.31 versus $5.57 expected and revenue at $15.56 billion versus $14.71 billion expected. Second-quarter revenue grew 38% year-on-year, and the company raised guidance on revenues and EPS. Sales for Mounjaro and Zepbound increased significantly, each by $2.1 billion. Sales grew 38% to $10.81 billion. The company is developing an oral GLP-1 pill for weight loss, which is going to be the major catalyst of LLY future growth, even though the trial results have been a little disappointing, with just 12% weight loss, while Wall Street was expecting around 15%. LLY is facing the risk of potential drug price controls from President Trumps. The analyst does not currently own LLY. Using analyst estimates for 37% growth in 2026, then decelerating growth to 15% by 2030. Using PE ratio of 25 and a 1% dividend, it shows 129% upside to $1434 per share, and it is required $717 per share to get a double on LLY.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
100%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail